03Recent Activity
Sava announces $19M Series A led by Balderton Capital.
AUG 2025
Sava is developing the first-ever multi-molecule biosensing wearable capable of detecting biomarkers just below the skin’s surface, enabled by its novel microsensing technology
Sava is developing the first-ever multi-molecule biosensing wearable capable of detecting biomarkers just below the skin’s surface, enabled by its novel microsensing technology. Its initial device is a pain-free, low-cost, and accurate Continuous Glucose Monitor (CGM) aimed at transforming diabetes care and expanding access to real-time health monitoring.